X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs IPCA LABS - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD IPCA LABS BIOCON LTD/
IPCA LABS
 
P/E (TTM) x 92.4 28.3 326.7% View Chart
P/BV x 7.8 3.4 233.4% View Chart
Dividend Yield % 0.1 0.1 105.7%  

Financials

 BIOCON LTD   IPCA LABS
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
IPCA LABS
Mar-18
BIOCON LTD/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,188695 170.8%   
Low Rs305400 76.3%   
Sales per share (Unadj.) Rs68.7260.2 26.4%  
Earnings per share (Unadj.) Rs7.619.0 39.8%  
Cash flow per share (Unadj.) Rs14.033.1 42.3%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.10.2 73.4%  
Book value per share (Unadj.) Rs86.3213.0 40.5%  
Shares outstanding (eoy) m600.00126.20 475.4%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.92.1 516.0%   
Avg P/E ratio x98.928.9 342.4%  
P/CF ratio (eoy) x53.416.6 322.5%  
Price / Book Value ratio x8.62.6 336.3%  
Dividend payout %13.25.3 251.2%   
Avg Mkt Cap Rs m447,90069,120 648.0%   
No. of employees `0006.113.3 46.4%   
Total wages/salary Rs m9,3117,359 126.5%   
Avg. sales/employee Rs Th6,705.82,477.4 270.7%   
Avg. wages/employee Rs Th1,514.2555.2 272.7%   
Avg. net profit/employee Rs Th736.9180.6 407.9%   
INCOME DATA
Net Sales Rs m41,23432,836 125.6%  
Other income Rs m2,062418 493.3%   
Total revenues Rs m43,29633,254 130.2%   
Gross profit Rs m8,2914,505 184.0%  
Depreciation Rs m3,8511,777 216.7%   
Interest Rs m615240 256.0%   
Profit before tax Rs m5,8872,905 202.6%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,569511 307.0%   
Profit after tax Rs m4,5312,394 189.2%  
Gross profit margin %20.113.7 146.6%  
Effective tax rate %26.717.6 151.5%   
Net profit margin %11.07.3 150.7%  
BALANCE SHEET DATA
Current assets Rs m41,48619,455 213.2%   
Current liabilities Rs m21,41310,076 212.5%   
Net working cap to sales %48.728.6 170.4%  
Current ratio x1.91.9 100.3%  
Inventory Days Days6498 65.3%  
Debtors Days Days9467 140.7%  
Net fixed assets Rs m50,66120,260 250.1%   
Share capital Rs m3,000252 1,188.6%   
"Free" reserves Rs m48,80826,633 183.3%   
Net worth Rs m51,80826,886 192.7%   
Long term debt Rs m17,8982,340 764.8%   
Total assets Rs m99,89741,173 242.6%  
Interest coverage x10.613.1 80.7%   
Debt to equity ratio x0.30.1 396.9%  
Sales to assets ratio x0.40.8 51.8%   
Return on assets %5.26.4 80.5%  
Return on equity %8.78.9 98.2%  
Return on capital %9.610.8 89.5%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m12,05815,642 77.1%   
Fx outflow Rs m7,3484,884 150.5%   
Net fx Rs m4,71010,759 43.8%   
CASH FLOW
From Operations Rs m6,6213,411 194.1%  
From Investments Rs m-6,840-1,354 505.2%  
From Financial Activity Rs m-2,397-1,304 183.8%  
Net Cashflow Rs m-2,612753 -346.8%  

Share Holding

Indian Promoters % 40.4 45.9 88.0%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 11.4 73.7%  
FIIs % 10.7 25.3 42.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 17.4 114.4%  
Shareholders   109,995 36,892 298.2%  
Pledged promoter(s) holding % 0.0 2.1 1.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Recovers after Crashing Over 1000 Points; DHFL Tanks 50%(01:30 pm)

Stock markets in India plunged in the afternoon session today. The BSE Sensex recovered after tanking 1,000 points in intra-day deals.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 21, 2018 03:35 PM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS